Premium
Effects of su‐13437, a new hypolipidemic drug, upon synthesis in vivo of hepatic and carcass total fatty acids and total cholesterol
Author(s) -
Cenedella Richard J.
Publication year - 1971
Publication title -
lipids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.601
H-Index - 120
eISSN - 1558-9307
pISSN - 0024-4201
DOI - 10.1007/bf02531232
Subject(s) - clofibrate , chemistry , in vivo , medicine , cholesterol , lipidology , clinical chemistry , triglyceride , fatty liver , endocrinology , fatty acid synthesis , fatty acid , biochemistry , biology , microbiology and biotechnology , disease
The present study is directed toward obtaining information on the metabolic effects and on the mode of action of CIBA‐Su‐13437, a new hypolipidemic phenolic ether structurally related to clofibrate. The ability of Su‐13437 to affect the net formation of lipids in vivo was studied by measuring the total incorporation of intraperitoneally injected 1,2‐ 14 C‐sodium acetate and uniformly labeled 14 C‐glucose into total fatty acids and total cholesterol by the liver and carcass of control and Su‐13437‐treated mice. Treated mice received Su‐13437 orally at 25, 100 or 250 mg/kg/day for 14 or 15 consecutive days. Treatment with Su‐13437 resulted in pronounced enlargement of the liver and significant reductions in the plasma levels of triglycerides and total cholesterol. Essentially all of the observed metabolic effects of Su‐13437 were confined to the liver. At all doses studied, in addition to liver enlargement, there were large increases in incorporation of both 14 C‐acetate and 14 C‐glucose carbon into hepatic total fatty acids; marked increases in hepatic total fatty acid content; and decreases in the liver's relative cholesterol content of up to 30% with little or no effect upon the net synthesis of cholesterol per gram of liver. These observations are interpreted as indicating that Su‐13437 lowers plasma triglyceride and cholesterol levels by means other than net inhibition of fatty acid and cholesterol formation by either hepatic or extrahepatic tissues.